Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus ...Middle East

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib in a new trial shows that efficacy extends to cutaneous lupus. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus )

Also on site :

• Opinion: Tolerance of diversity is central to San Diego’s economic growth
• De Anza College physical education complex to undergo $53 million renovation
• ‘Deeply concerned’ over India press censorship, says X as accounts blocked